Connect with us

Press Release

CytoMed Therapeutics Ltd — A Rising Star in Singapore’s Cancer Biotechnology Sector

Published

59 minutes ago

on

In February 2026, The Wall Street Transcript published an exclusive interview with CytoMed Therapeutics Ltd (NASDAQ: GDTC) Chairman Choo Chee Kong. The interview covered the company’s technological approach, clinical trial progress, global strategic expansion — particularly in China and India — financing status, and deep insights into the global biotechnology industry.
 
 1. Company Overview & Core Technology
Company Background
CytoMed is a clinical-stage biotech spin-off from ASTAR, Singapore’s national scientific research agency. The company focuses on developing affordable cancer therapy using patented allogeneic Gamma Delta T Cells derived from healthy donors.
Mission
The company aims to address the major limitations of existing cell therapies such as CAR-T, including high treatment costs and lengthy manufacturing timelines. By using blood from healthy donors to manufacture “off-the-shelf” immune cells, the company aims to reduce production costs and enable global distribution.
Technological Advantages
Safety
Gamma Delta T Cells have a lower risk of causing Graft-versus-Host Disease (GVHD), making them suitable for allogeneic transplantation.
Versatility
The cells express CARs (Chimeric Antigen Receptors) targeting NKG2D ligands, enabling recognition of multiple cancer types that express stress-related molecules, including Solid tumors & Hematological malignancies.
 
 2. Clinical Trial Progress
Singapore ANGELICA Trial
Nature of the Trial
Ongoing first-in-human clinical trial targeting patients with:
Advanced solid tumors
Hematological malignancies
Progress
The trial comprised 12 patients in total, and treatment has been completed for half of the participants (6 patients).
Objective
To complete the Phase 1 clinical trial and evaluate before embarking on Phase 2 by next year 2027:
Safety
Efficacy of the CAR-modified version
 
Malaysia Clinical Trial
Strategy
CytoMed plans to launch a first-in-human clinical trial for the unmodified version of the therapy, which is expected to be significantly less expensive than the CAR-T version.
Collaboration
The company is collaborating with Universiti Malaya Hospital and is preparing to submit trial documentation to regulators and start by this year 2026.

3. Strategic Expansion & Acquisitions
Acquisition of TC BioPharm (UK)
Through this acquisition, CytoMed obtained feeder-free manufacturing technology, solving logistical challenges associated with cross-border transportation of specialized feeder cells and strengthening its cancer therapy platform.
 
Acquisition of Longevity Bank (Malaysia)
Background
In mid-2024, CytoMed acquired a Malaysian cord blood bank that had entered liquidation due to the impact of the pandemic. The bank had approximately 12,000 customers.
Strategic Purpose
The acquisition provides access to cord blood resources for the development of Natural Killer (NK) Cell therapies from pristine cord blood.
NK cells have potential applications in:
Anti-aging
Elimination of senescent cells
This acquisition also broadens the company’s therapeutic pipeline.
 
 4. Global Market Strategy: Focus on China & India
China (Key Strategic Focus)
Policy Opportunity
CytoMed is closely monitoring China’s “Directive 818,” which allows hospitals conducting investigator-initiated trials (IITs) to charge patients, thereby helping subsidize biotechnology companies’ R&D and manufacturing costs.
Competitive Advantage
Compared with the capital-intensive “cash-burning” model commonly seen in Western biotech companies, the Chinese model is viewed as more sustainable.
China’s Government-backed biotech parks, Pragmatic regulatory policies & Strong venture capital ecosystem have made the country highly attractive for biotechnology development.
Market Potential
China has a massive cancer patient population and  regulatory flexibility for compassionate-use style commercialization making it a critical strategic market for CytoMed.
 
India
As one of the world’s two largest population centres, India is also a major target market for the company.
 
United States
Although CytoMed collaborates with MD Anderson Cancer Center — where animal studies showed effectiveness against AML — the company currently does not prioritize the U.S. market due to the long time and extremely high cost of clinical trials.
 
 5. Financial Position & Industry Perspectives
Financial Status
The company raised only USD 8 million during its 2023 IPO due to difficult biotech market conditions at the time.
However, management has maintained disciplined spending while seeking partners to co-develop its proprietary allogeneic cancer technologies.

View on the “Biotech Winter”
The Chairman believes the biotech industry is currently experiencing a “winter” caused by:
Excessively high valuations during the pandemic era
SPAC-related speculation
Significant investor losses
Tightening capital markets
The company also faces:
Heavy short-selling pressure
Interference from day traders

Strategic Pivot
To survive the difficult funding environment, CytoMed is shifting toward closer collaboration with hospitals to provide treatments for “no-option” patients.
The company benefits from low cost infrastructure in Southeast Asia and aims to:
Attract international medical tourists
Leverage Malaysia’s “Medical Tourism Year 2026”
Generate revenue while simultaneously collecting clinical data
 
 6. Regulatory Advocacy
Compassionate Use
CytoMed advocates for regulators to adopt a more flexible approach for terminal patients who have exhausted all available treatment options, allowing access to new cell therapies.
East-West Differences
The Chairman noted that Eastern societies, particularly in Southeast Asia, generally have less aggressive litigation cultures compared with Western countries such as the United States.
This creates a more favourable environment for Compassionate Use programs, allowing terminal patients to try innovative therapies when conventional options have failed.
 
Conclusion
The interview highlights CytoMed’s unique “low-cost survival strategy” within the highly expensive biotechnology sector.
By leveraging:
Southeast Asia’s lower manufacturing and labour costs
Strategic hospital partnerships
China’s “Directive 818” policy framework
the company has identified a pragmatic commercialization pathway during the ongoing biotech capital winter.
CytoMed’s approach demonstrates not only technological ambition, but also strong strategic insight into the evolving global biotechnology landscape.
 

Media Contact: 

Media Relations
CytoMed Therapeutics Ltd
Singapore
https://www.cytomed.sg/

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

Baiyunshan Hanfang Pharmaceutical Releases Technical Progress on Industrial High-Purity Lipid Raw Materials

Published

2 minutes ago

on

May 21, 2026

By

This Enterprise Unveils Industrial High-Purity Lipid Raw Material Product Portfolio for Global Fine Chemical Clients

Guangzhou, Guangdong, China, 21st May 2026 – Guangzhou Hanfang Pharmaceutical Company Limited. (a subsidiary of Guangzhou Pharmaceutical Holdings Limited) today announced updates to its industrial lipid raw material product portfolio and global service upgrades. The company’s offerings include industrial high-purity egg yolk lecithin, medium-chain triglycerides, and soybean oil (general-purpose raw material), tailored to meet industrial production requirements across multiple regions. Adopting a comprehensive business model encompassing direct sales, distribution, custom processing, and technical support, the enterprise serves over 1,000 clients worldwide with a business network spanning more than 20 countries and regions, further expanding its global fine chemical supply chain footprint.

Core Product Portfolio and Technical Services

Guangzhou Baiyunshan Hanfang Pharmaceutical provides products and services tailored for industrial fine chemical enterprises and related industries:

  • Industrial High-Purity Lipid Raw Materials: Supplies industrial high-purity egg yolk lecithin, medium-chain triglycerides, and soybean oil (general-purpose raw material), serving as core components for emulsifiers, cosolvents, and industrial energy additive raw materials, complying with process standards for industrial production scenarios.
  • Customization and Technical Support: Delivers customized solutions for exclusive raw material formulation needs, including compliant adjustments to component ratios and performance parameters; the technical team provides end-to-end guidance on production process applications.
  • Comprehensive Business Model: Covers direct sales, authorized distribution, custom processing, and technical services, meeting diverse needs from standard orders to customized projects.

Global Compliance and Quality Standards

The enterprise has established operational and quality systems aligned with international fine chemical supply chain norms. Its production base in Conghua, Guangzhou, adopts fully controlled end-to-end processes to ensure consistent product quality. Products are sold across Asia, Europe, and other regions, with efficient delivery enabled by mature logistics channels.

Supply and Service Information

Products are available globally through the direct sales team and authorized distributors. Orders are accepted from industrial fine chemical enterprises and related manufacturers, with standard production lead times provided. Custom processing services are available for premium clients, alongside formulation technical consultations. Clients may inquire via the official website or regional sales representatives.

“We focus on ensuring the stability of the fine chemical supply chain, with deep expertise in the lipid raw material sector,” said Chen Shiqi, Project Manager at Guangzhou Baiyunshan Hanfang Pharmaceutical. “We are committed to delivering stable, reliable products and technical support to meet the evolving needs of our global clients.”

Industry Background and Strategic Direction

Industry data indicates sustained growth in global demand for high-quality industrial lipid raw materials, driven primarily by the expansion of global fine chemical production capacity and the need for supply chain resilience. As a member enterprise of Guangzhou Pharmaceutical Holdings Limited, Baiyunshan Hanfang closely follows trends in the fine chemical supply chain industry, focusing on product stability and global technical services to support the growth of clients worldwide.

Future Plans

Guangzhou Baiyunshan Hanfang Pharmaceutical will continue to increase investment in production capacity and product R&D, with plans to expand its global distribution network, upgrade technical service systems for international clients, and prioritize meeting the diverse production needs of core markets.

About Guangzhou Hanfang Pharmaceutical Company Limited

Founded in 1998 and headquartered in Guangzhou, Guangzhou Hanfang Pharmaceutical Company Limited employs more than 330 people across production, R&D, quality control, and administration. The enterprise specializes in industrial fine chemical raw materials, lipid raw materials, and supporting technical services, with products sold in over 20 countries and regions. It holds multiple patents for lipid processing technologies, with its Conghua production base serving as the core production hub. The enterprise’s mission is “stable supply, technical collaboration, empowering the global fine chemical industry.”
For more information, please visit the official website: https://www.byshanhanfang.com/

Media Contact

Organization: Guangzhou Hanfang Pharmaceutical Company Limited

Contact Person: Ms. Chen Shiqi

Website: https://www.byshanhanfang.com/

Email: Send Email

Contact Number: +8613427652966

Address:No. 8 Wenquan Avenue, Wenquan Town, Conghua District, Guangzhou Guangdong Province, P.R. China

City: Guangzhou

State: Guangdong

Country:China

Release id:45292

The post Baiyunshan Hanfang Pharmaceutical Releases Technical Progress on Industrial High-Purity Lipid Raw Materials appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Turn Energy into Profit Gareth Evans’ Newly Released Book Urges Businesses to Build Their Own Energy Infrastructure

Published

14 minutes ago

on

May 21, 2026

By

United States, 21st May 2026 – Renowned energy strategist and highly experienced business leader Gareth Evans has released his book, Powering Profits: Control Energy Costs, Build Resilience, and Gain a Lasting Competitive Advantage. The new book is an invaluable corporate leadership guide that offers a deep dive into how power systems work and urges businesses to rethink their energy strategy. It provides actionable strategies for business leaders to reduce costs and gain a competitive advantage.

Powering Profits is an insightful executive playbook that provides a strategic framework for CEOs, business leaders, and entrepreneurs to prioritize control, enhance adaptability, and achieve measurable financial outcomes by reimagining their energy strategy. At a time when energy policies and political issues are reshaping the global business landscape, the new book serves as a timely educational resource, highlighting the business risks of relying on aging energy systems that are not only overburdened by rapid business expansion but also vulnerable to extreme weather events and supply chain disruptions. Drawing on years of experience and research across complex energy systems in various industries, the author illuminates a path forward in which self-managed energy can not only protect organizations from disruptions and rising costs but also offer a strategic advantage over time, turning energy into a scalable asset.

Gareth Evans is passionate about helping businesses generate clean, on-site energy that is reliable, affordable, and a powerful asset that drives growth and revenue. Having worked and lived across six continents, he has seen firsthand how centralized energy systems are unreliable and unfair. As the CEO and co-founder of VECKTA, he has dedicated his professional life to empowering businesses to own their power, delivering solutions that improve operational efficiency and create long-term value.

In addition to authoring the Powering Profits Substack, Gareth is the co-host of the Renewable Rides podcast, where he shares his expertise with executives and CEOs across industries. He has worked with globally recognized companies, including Worley, a global leader in reshaping energy solutions. 

Gareth Evans is available for interviews. 

Title: Powering Profits: Control Energy Costs, Build Resilience, and Gain a Lasting 

                               Competitive Advantage

Author: Gareth Evans

Contact: Michael DeLon

Company: Paperback Expert

Email: press@PaperbackExpert.com 

Phone Number:  (501) 404-8690

About Gareth Evans:  https://veckta.com/our-company/#theteam

Availability: Amazon.com

Book Preview:  https://www.amazon.com/dp/B0H1XCVQ31

Media Contact

Organization: Paperback Expert

Contact Person: Michael DeLon

Website: https://paperbackexpert.com/

Email: Send Email

Contact Number: +15014048690

Country:United States

Release id:45325

The post Turn Energy into Profit Gareth Evans’ Newly Released Book Urges Businesses to Build Their Own Energy Infrastructure appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Modern Financial Planning! Brian K. Peterson’s Newly Released Book Redefines How Blended Families Navigate Money

Published

14 minutes ago

on

May 21, 2026

By

United States, 21st May 2026 – Certified Financial Planner practitioner and wealth management expert Brian K. Peterson has released his book, Blended Family Finances: How to Talk About Money, Plan for the Future, and Build a Life You Love. The new book is a transformative financial planning guide for blended families. It offers a deeply human approach to long-term money management that also accounts for relationships and family values.

Blended Family Finances is a timely guide for today’s evolving family structures, addressing the unique issues blended families face. It offers a flexible roadmap rooted in communication and shared purpose, providing clarity and support to families after loss, divorce, or remarriage. Through real-life stories, the book outlines three key steps: having open conversations about money, creating a shared vision, and using practical strategies for protection. It emphasizes emotional aspects often overlooked in traditional financial planning, filling an important gap.

Brian K. Peterson is a Certified Financial Planner practitioner and a Certified Private Wealth Advisor® with a passion for helping blended families plan for a stable, secure financial future. As a dad in a blended family, his personal experience complements his professional expertise, enabling him to help families achieve their financial goals through meaningful communication and intentional living. Widely known as “The Financial Planner for Blended Families™,” he is the founder of Blended Family Financial.

Over the years, Brian has developed his proprietary framework, the Planning Built for Life® process, which helps couples move beyond traditional planning and navigate money matters with confidence and unity. His new book combines his unique philosophy with practical financial knowledge, empowering families to create a better life. 

Brian K. Peterson CFP® is available for interviews. 

Title: Blended Family Finances: How to Talk About Money, Plan for the Future,  

                                  and Build a Life You Love

Author: Brian K. Peterson CFP®

Contact: Michael DeLon

Company: Paperback Expert

Email: press@PaperbackExpert.com 

Phone Number:   (501) 404-8690

About Brian K. Peterson:  https://www.blendedfamilyfinancial.com/about

Availability: Amazon.com

Book Preview:      https://www.amazon.com/dp/B0GX2ZQRK9 

Media Contact

Organization: Paperback Expert

Contact Person: Michael DeLon

Website: https://paperbackexpert.com/

Email: Send Email

Contact Number: +15014048690

Country:United States

Release id:45324

The post Modern Financial Planning! Brian K. Peterson’s Newly Released Book Redefines How Blended Families Navigate Money appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us